CONCEPT: StemBANCC is a large-scale, five-year academic-industry partnership in the area of stem cell research. It brings together a consortium of 37 partners from pharmaceutical companies, research institutions and small and medium enterprises (SMEs) who collaborate and share their experience to exploit the rich expertise across sectors and enhance knowledge transfer between academia and industry for patient benefit.

MAIN OBJECTIVE: The main aim of the StemBANCC project is to generate and characterise high quality human induced pluripotent stem (iPS) cell lines to study a range of chronic diseases and test for drug efficacy and safety. The five major disease groups of interest are peripheral neuropathies, neurodegenerative disorders, neurodysfunctional disorders, diabetes and adverse drug responders.